Outcomes of reduction hepatectomy combined with postoperative multidisciplinary therapy for advanced hepatocellular carcinoma

Table 4 Comparison between the postoperative complete remission (+) and postoperative complete remission (-) groups

	Category	POCR (+)	POCR (-)	P value
Age	< 60/≥ 60	1/7	11/11	0.0994
Sex	Male/female	7/1	21/1	0.4690
HBV and/or HCV	-/ +	0/8	6/16	0.1550
Alb (g/dL)	< 3.7/≥ 3.7	5/3	10/12	0.6817
T-Bil (mg/dL)	≤ 0.8/> 0.8	6/2	13/9	0.6722
PT (%)	< 90/≥ 90	4/4	9/13	0.6976
ICGR15 (%)	< 15/≥ 15	4/4	14/8	0.6779
AFP (ng/mL)	< 200/> 200	4/4	12/10	1.0000
PIVKA-II	< 100/≥ 100	2/6	1/21	0.1655
Child-pugh class	A/B	8/0	19/3	0.5448
Tumor size (cm)	< 10/≥ 10	5/3	10/12	0.6817
Differentiation	wel or mod/por	5/3	12/10	1.0000
pN	-/ +	7/1	21/1	0.4690
Macrovascular invasion	-/ +	0/8	5/17	0.2868
Distant metastasis	-/ +	8/0	19/3	0.5448
BCLC stage	B/C	3/5	9/13	1.0000
Anatomical hepatectomy	-/ +	2/6	1/21	0.1665
Number of tumors in the remnant liver	1-3/≥ 4	7/1	5/17	0.0025a

^aP < 0.05. POCR: Postoperative complete remission; PT: Prothrombin time; ICGR15: Indocyanine green retention rate at 15 min; AFP: Alpha-fetoprotein; PIVKA-II: Protein induced by vitamin K absence/antagonist-II; BCLC: Barcelona Clinic Liver Cancer.